Outsmarting immune suppression through GPCR innovation
Immune resistance is one of cancer’s toughest tricks. By rethinking how we target GPCRs, scientists may finally have a way to modulate it with precision.
List view / Grid view
Immune resistance is one of cancer’s toughest tricks. By rethinking how we target GPCRs, scientists may finally have a way to modulate it with precision.
26 February 2021 | By Domain Therapeutics
Watch our on-demand webinar which focused on the progress achieved in G protein-coupled receptor (GPCR) therapeutic antibody-based discovery and development.
29 February 2016 | By Victoria White
PeptiMimesis is a new biotech startup developing a novel class of therapeutic peptides using a breakthrough technology...
4 March 2015 | By Domain Therapeutics
Kaldi Pharma granted its first license to CleveXel Pharma, who will develop a preclinical candidate for Parkinson’s disease...
4 February 2014 | By Domain Therapeutics
DTect-All(TM) platform will be used to screen for GPCR-directed allosteric modulator antibodies...